You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Biogen
since
auto-detected in 8 stories
6 hours ago
Biogen could see lower royalties for Ocrevus after its patent expires , but it has developed other medicines that will support its growth, per Piper Sandler.
14 days ago
Biogen to buy Apellis Pharmaceuticals for $5.6 billion to expand its rare disease portfolio ⊕
Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio of rare-disease medicines.
90 days ago
Stocks making the biggest moves midday: Biogen, Rivian, Bank of America, Airbnb & more ○
These are the stocks posting the largest moves in midday trading.
5 months ago
Stifel upgrades biotech stock on a narrative shift in Alzheimer’s treatment ○
Stifel sees Biogen stock rallying nearly 32% from here.
7 months ago
Stocks making the biggest moves midday: Frontier Group, Kraft Heinz, Biogen and more ○
These are the stocks posting the largest moves in midday trading.
Stocks making the biggest premarket moves: Kraft Heinz, PepsiCo, Biogen, Signet Jewelers and more ○
These are the stocks posting the largest moves in the premarket.
US regulator approves at-home Alzheimer’s drug from Eisai and Biogen ○
found
a story from Financial Times ✅ › Financial Times
Go ahead for Leqembi shot by Food and Drug Administration could help revive two companies’ sluggish sales
13 months ago
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short ○
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.
page 1 of 1